News

National MS Society Honors LyondellBasell with ‘Circle of Distinction Award’ for Raising $1.4M

LyondellBasell, an established nameĀ in the plastics, chemical and refining industry, has been honored withĀ theĀ Circle of Distinction Award from theĀ National Multiple Sclerosis SocietyĀ for raising $1.4 million to benefitĀ the society and the multiple sclerosis (MS) community. Since 1998, the company has participated in the MS Society’s annual fundraiser in…

Fluorosamine Seen to Boost Remyelination in MS Mouse Model by Blocking Scarring Molecules

AĀ substance called fluorosamine was seen to boost remyelination in mice by preventing the synthesis of chondroitin sulfate proteoglycans and by promoting oligodendrocyte function. The findings showed that targeting molecules that block remyelination may be a promising therapeutic approach in multiple sclerosis (MS). Upregulation of chondroitin sulfate proteoglycans ā€” large molecules…

Severe Rebound Effects Found in ‘Relevant’ Number of MS Patients After Stopping Fingolimod

Rebound symptoms after stoppingĀ fingolimod (Gilenya) treatment affect a “clinically relevant” number of multiple sclerosis (MS) patients,Ā a study byĀ University of California, San Francisco, researchers reported. The study called attention to the need for determining the best method of sequencing or stopping MS treatments, and highlighted the need to identify factors…

New Phase 2 Trial of a B-cell Antibody, TG-1101, to Treat Relapsing MS Getting Underway

TG TherapeuticsĀ recently announced the opening of a newĀ clinical trial evaluating TG-1101, its glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (RRMS). The Phase 2 clinical trial, titled “A Placebo-Controlled Multi-Center Phase 2 Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients…

Opexa’s CEO Gives Update on T-Cell Therapy at Vatican Conference

Opexa Therapeutics, Inc., announced that itsĀ president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and itsĀ potential forĀ treating autoimmune disorders, includingĀ multiple sclerosis, at the recentĀ Cellular Horizons:Ā The Third International Conference on the Progress of Regenerative Medicine and its Cultural ImpactĀ held at the Vatican. Neil…

European Program Aims to Develop Wearable Devices to Monitor and Treat MS

A major new European research program to develop waysĀ of monitoring three mainĀ central nervous system diseases ā€”multiple sclerosis (MS), depressive disorder, and epilepsy ā€” using wearable devices and smartphones was launched on April 26. The RADAR-CNS (Remote assessment of disease and relapse Central Nervous System) project, supported by the Innovative…

$185M Gift to UCSF Will Support New Neurosciences Institute

A gift worthĀ $185 million from Joan and Sanford I. Weill toĀ the University of California San FranciscoĀ (UCSF) will allow the university to expand itsĀ neurosciences programs and facilities,Ā advancing its research work into psychiatric, neurological and neurodegenerative diseases, including multiple sclerosis (MS). The gift, the largest single donation in UCSF history, is…

Measures of Subtle Movements While Standing Detects Neurologic Problems in MS Patients and Athletes with Concussions

Researchers atĀ Purdue UniversityĀ haveĀ developed a method of identifying subtle oscillations in a personā€™s posture that mirror an excessive delay in neuromuscular responses, indicating a neurologic deficit. The oscillations, which differ from the normal tendency of a standing person to sway, mayĀ aid in diagnosing neuromuscular disorders such as multiple sclerosis (MS).

Gut Bacteria Affects Myelin Content and Induces MS-Like Depression in Mice, Study Reports

Researchers atĀ the Center of Excellence for Myelin Repair, a part of Mount Sinai, reportedĀ that gut bacteria produce compounds that were seen to affect theĀ myelinĀ content in mice and cause social avoidance behaviors. StudyĀ results indicated that targeting gut bacteria, or the gut metabolites, mightĀ help in treatingĀ neuropsychiatric disorders or complications, such as those…

MedDayā€™s MD1003, a Biotin, Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials

MedDayĀ recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials ofĀ its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active”Ā progressive MS and those with either relapsing or progressive MS andĀ visual loss, respectively. Data, presented at the recentĀ American…

At-Home ‘Brain Training’ Program for MS Patients Reported to Improve Cognitive Skills by 29%

Multiple sclerosis patients using a cognitive remediation computer training program, part ofĀ a controlled trial by researchers fromĀ NYU Langone Medical Center,Ā had greaterĀ improvements in cognitive function than those who used a placebo-training program, according to a presentationĀ at the recentĀ American Academy of NeurologyĀ annual meeting in Vancouver, Canada. Problems in attention, memory,…

#CMSC16 – MS Experts Agree on Benefits of Vitamin D Supplements, Despite Mostly Circumstantial Evidence

A roundtable discussion, provided as a webinarĀ organized by theĀ Consortium of Multiple Sclerosis Centers (CMSC)Ā in advance of its June conference, considered the role of vitamin D in multiple sclerosis (MS). Researchers concluded that, while evidence is only circumstantialĀ as to theĀ vitamin’s ability to prevent disease relapses, its multiple health benefits justify…

Florida Atlantic University Researcher Awarded $540K NIH Grant to Research Collagen Degradation in Diseases Like MS

A researcher atĀ Florida Atlantic University (FAU)Ā has been awarded a $540,250 grant from the National Cancer Institute, part of the National Institutes of Health, to support continued research into the collagen degradative processesĀ linked to connective tissueĀ diseasesĀ likeĀ multiple sclerosis (MS). Dr. Gregg Fields, a professor and chair of the Department of Chemistry and…

Biogen and AbbVie Present New Data Showing Zinbryta, an RRMS Drug Candidate, Aids Cognition Without Immune Depletion

New data presented byĀ BiogenĀ andĀ AbbVieĀ at the recent 68th annual meeting of theĀ American Academy of Neurology (AAN) showed that ZinbrytaĀ (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results ā€” from post-hoc analyses of clinicalĀ trials ā€” also offer a better…